Bicycle Therapeutics (NASDAQ:BCYC) Share Price Breaks Above 50 Day Moving Average - Should You Sell?

Key Points

• Bicycle Therapeutics shares moved above their 50-day moving average, reaching $3.84 before last trading at $3.77; the 50-day average was $3.75.
• Analyst views are mixed: five rate the stock Buy, three Hold and two Sell, producing an overall Hold rating and an average price target of $13.57.
• The company reported a quarterly loss of $0.15 per share, better than the $0.40 loss analysts expected, while revenue of $34.06 million also exceeded estimates of $12.22 million.

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.75 and traded as high as $3.84. Bicycle Therapeutics shares last traded at $3.77, with a volume of 590,237 shares changing hands.

Analysts Set New Price Targets

BCYC has been the topic of several research reports. Jefferies Financial Group reissued a "buy" rating and issued a $10.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, October 29th. Needham & Company LLC lowered their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Zacks Research downgraded shares of Bicycle Therapeutics from a "hold" rating to a "strong sell" rating in a report on Wednesday, October 14th. Wall Street Zen upgraded shares of Bicycle Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, October 31st. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Bicycle Therapeutics in a research report on Friday, October 2nd. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $13.57.

Bicycle Therapeutics Trading Up 4.4%

The company has a market cap of $263.86 million, a P/E ratio of -1.86 and a beta of 1.59. The business's 50 day simple moving average is $3.75 and its 200 day simple moving average is $4.49.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.25. The business had revenue of $34.06 million during the quarter, compared to analyst estimates of $12.22 million. Bicycle Therapeutics had a negative net margin of 169.75% and a negative return on equity of 26.02%. Sell-side analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -2.11 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BCYC. R Squared Ltd bought a new position in shares of Bicycle Therapeutics in the third quarter worth about $98,000. Alps Advisors Inc. raised its stake in Bicycle Therapeutics by 30.1% during the 3rd quarter. Alps Advisors Inc. now owns 66,501 shares of the company's stock valued at $245,000 after purchasing an additional 15,379 shares during the period. Vontobel Holding Ltd. raised its stake in Bicycle Therapeutics by 15.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company's stock valued at $85,000 after purchasing an additional 3,000 shares during the period. Portland Investment Counsel Inc. bought a new stake in Bicycle Therapeutics during the 2nd quarter valued at approximately $64,000. Finally, Marquette Asset Management LLC purchased a new position in Bicycle Therapeutics in the 2nd quarter worth approximately $309,000. Institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics' research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.